SAN FRANCISCO (EGMN) - Women with the most common, least aggressive subtype of breast cancer do not benefit from the addition of paclitaxel to adjuvant chemotherapy, according to a study using tissue microarrays.Investigators analyzed breast tissue from 2,039 women with node-positive, early-stage breast cancer who participated in the CALGB (Cancer and Leukemia Group B) study 9344 in the 1990s. CALGB 9344 had reported an overall 5% absolute improvement in disease-free survival in women randomized...